G. Sotgiu (Porto Torres (SS), Italy), K. Dheda (Cape Town, South Africa)
Pyrosequencing(PSQ) in early diagnosis of CNS tuberculosis and determining drug resistance. A. Bhosle (Mumbai, India), P. Singhal (Mumbai, India), V. Pardasani (Mumbai, India), P. Lunia (Mumbai, India), K. Ajbani (Mumbai, India), D. Dhangar (Mumbai, India), S. Tiple (Mumbai, India)
|   |
A study to perceive the role and function of Proteasome Accessory Factor-C (PafC) inMycobacterium tuberculosis. A. NARAIN (LUCKNOW, India), E. Dhamija (LUCKNOW, India), K. Srivastava (LUCKNOW, India), K. Srivastava (LUCKNOW, India), S. Kant (LUCKNOW, India)
|   |
Elucidation of Protein Tyrosine Phosphatase-B for its role in intracellular survival of Mycobacterium tuberculosis E. Dhamija (Lucknow, India), S. Yabaji (Lucknow, India), A. Chatterjee (Lucknow, India), A. Mishra (Lucknow, India), R. K.Dubey (Lucknow, India), A. Narain (Lucknow, India), K. K. Srivastava (Lucknow, India)
|  |
In silico validation of anti-tuberculosis activity and identification of lead molecules in Annona squamosa S. Basheera (Trivandrum, India), S. Sivanandan (Trivandrum, India), B. Charuvilkamalan (Trivandrum, India)
|  |
Decreased miR-150-5p and miR-23a-3p expressions in patients with active Pulmonary Tuberculosis (TB) disease Y. Chen (Kaohsiung, Taiwan), M. Lin (Kaohsiung, Taiwan), C. Lee (Kaohsiung, Taiwan), Y. Zheng (Kaohsiung, Taiwan), W. Fang (Kaohsiung, Taiwan)
|  |
The efficacy of single-photon emission computed tomography with Macrotech 99m-Tc radiopharmaceutical in microcirculation evaluation in patients with fibrous-cavernous pulmonary tuberculosis R. Kazho (Moscow, Russian Federation), N. Karpina (Moscow, Russian Federation), A. Sigaev (Moscow, Russian Federation), R. Amansahedov (Moscow, Russian Federation)
|   |
Serum microRNA markers of tuberculoma decoy. V. Evstifeev (Moscow, Russian Federation), G. Shepelkova (Moscow, Russian Federation), A. Ergeshova (Moscow, Russian Federation), A. Guskov (Moscow, Russian Federation), M. Bagirov (Moscow, Russian Federation), V. Yeremeev (Moscow, Russian Federation)
|  |
The increased production level of 15 cytokines associated with tuberculosis severity and patients’ responsiveness to therapy. I. Nikitina (Moscow, Russian Federation), Y. Serdyuk (Moscow, Russian Federation), T. Nenasheva (Moscow, Russian Federation), T. Bagdasaryan (Moscow, Russian Federation), V. Shorokhova (Moscow, Russian Federation), I. Lyadova (Moscow, Russian Federation)
|  |
From environmental bacteria to obligate pathogen: the study of adaptations enhancing the persistence of tuberculosis bacilli A. Allen (Toulouse 31000, France), W. Malaga (Toulouse 31000, France), C. Astarie-Dequeker (Toulouse 31000, France), A. Hassan (Toulouse 31000, France), C. Berrone (Toulouse 31000, France), F. Moreau (Toulouse 31000, France), P. Supply (Lille 59000, France), R. Brosch (Paris 75015, France), C. Guilhot (Toulouse 31000, France)
|   |
Indoleamine 2,3-dioxygenase-1 (IDO1) activity protects M. tuberculosis in macrophages from antibiotics L. Guo (Amsterdam, Netherlands), A. Dijkhuis (Amsterdam, Netherlands), N. Van Der Wel (Amsterdam, Netherlands), R. Lutter (Amsterdam, Netherlands)
|  |
The Glutoxim influence on minimum inhibitory concentration of isoniazid-resistant strains of Mycobacterium tuberculosis N. Solovieva (St. Petersburg, Russian Federation), O. Kulikova (St. Petersburg, Russian Federation), Z. Rakisheva (Astana, Kazakhstan), G. Balasaniantc (St. Petersburg, Russian Federation)
|  |
Role of TLR2 Polymorphism (2258) in Susceptibility to Pulmonary Tuberculosis Y. Benbetka (Alger, Algeria), K. Saadi (Alger, Algeria), A. Fissah (Alger, Algeria)
|  |
Study of the Association of Functional Polymorphisms Affecting the TLR2, TIRAP, TNF, IL1B, IL1RN, IL12B and NOS2A Genes with Susceptibility to Pulmonary Tuberculosis. Y. Benbetka (Alger, Algeria), N. Djami (Alger, Algeria), A. Fissah (Alger, Algeria)
|  |
The attenuation of cytokine response might be correlated with gut dysbiosis in nontuberculous mycobacteria lung disease C. Shu (Taipei, Taiwan)
|  |
Hepatotoxic reactions in rats after administration of component schemes of reserve Anti-TB drugs with different safety profile A. Kazakov (Moscow, Russian Federation), G. Mozhokina (Moscow, Russian Federation), Y. Zyuzya (Moscow, Russian Federation), L. Petrova (Moscow, Russian Federation)
|  |
Mycobacterium tuberculosis shape and size variations in alveolar macrophages of tuberculosis patients E. Ufimtseva (Yekaterinburg, Russian Federation), N. Eremeeva (Yekaterinburg, Russian Federation), D. Vakhrusheva (Yekaterinburg, Russian Federation), S. Skornyakov (Yekaterinburg, Russian Federation)
|  |
In vitroM.tuberculosis H37Rv inhibition with levofloxacin encapsulated in PLGA particles E. Antonov (Moscow, Russian Federation), T. Smirnova (Moscow, Russian Federation), S. Andreevskaya (Moscow, Russian Federation), L. Chernousova (Moscow, Russian Federation), S. Bogorodski (Moscow, Russian Federation), V. Popov (Moscow, Russian Federation)
|  |
Efficiency of bactericidal activity of liposomal mycobacteriophages against intracellular Mycobacteria tuberculosis in the model of macrophages RAW 264 M. Vladimirsky (Moscow, Russian Federation), M. Lapenkova (Moscow, Russian Federation), Y. Alyapkina (Moscow, Russian Federation), I. Vasilyeva (Moscow, Russian Federation)
|  |
Efficacy of anti-tuberculosis therapy with INH, RIF and Bedaquiline in mice with different genetic susceptibility to the infection B. Nikonenko (Moscow, Russian Federation), I. Bocharova (Moscow, Russian Federation), M. Korotetskaya (Moscow, Russian Federation), E. Kondratieva (Moscow, Russian Federation), A. Apt (Moscow, Russian Federation)
|  |